# Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL

> **NCT05390749** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Orelabrutinib
- **DRUG:** Pomalidomide
- **DRUG:** Rituximab
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT05390749
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-11
- **Primary completion:** 2024-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-05-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05390749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05390749, "Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05390749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*